APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Liraglutide for The Treatment of Diabetes and Obesity

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Liraglutide for The Treatment of Diabetes and Obesity Industry Growth and Trends Forecast to 2032

Report ID 174008230127 December 202571 pages

Choose your research edition.

Industry ResearchLiraglutide for The Treatment of Diabetes and Obesity Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Liraglutide for The Treatment of Diabetes and Obesity Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Liraglutide for The Treatment of Diabetes and Obesity Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liraglutide for The Treatment of Diabetes and Obesity Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Liraglutide for The Treatment of Diabetes and Obesity Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Liraglutide for The Treatment of Diabetes and Obesity market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liraglutide for The Treatment of Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Liraglutide for The Treatment of Diabetes and Obesity include Huadong Medicine, Sino Biopharm, Teva and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Liraglutide for The Treatment of Diabetes and Obesity market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Liraglutide for The Treatment of Diabetes and Obesity market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Liraglutide for The Treatment of Diabetes and Obesity market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Liraglutide for The Treatment of Diabetes and Obesity.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Liraglutide for The Treatment of Diabetes and Obesity market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Liraglutide for The Treatment of Diabetes and Obesity Market by Company

Huadong Medicine

Sino Biopharm

Teva

Novo Nordisk

Liraglutide for The Treatment of Diabetes and Obesity Segment by Type

Generic Drug

Original Drug

Liraglutide for The Treatment of Diabetes and Obesity Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Liraglutide for The Treatment of Diabetes and Obesity Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liraglutide for The Treatment of Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liraglutide for The Treatment of Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liraglutide for The Treatment of Diabetes and Obesity.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Liraglutide for The Treatment of Diabetes and Obesity manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Liraglutide for The Treatment of Diabetes and Obesity in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Generic Drug Table 2. Major Company of Original Drug Table 3. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (K Units) Table 5. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type (2021-2026) Table 6. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (US$ Million) Table 7. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type (2021-2026) Table 8. Global Liraglutide for The Treatment of Diabetes and Obesity Price by Type (2021-2026) & (US$/Unit) Table 9. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2027-2032) & (K Units) Table 10. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type (2027-2032) Table 11. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2027-2032) & (US$ Million) Table 12. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type (2027-2032) Table 13. Global Liraglutide for The Treatment of Diabetes and Obesity Price by Type (2027-2032) & (US$/Unit) Table 14. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (K Units) Table 15. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (K Units) Table 17. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (K Units) Table 21. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2021-2026) & (US$ Million) Table 24. Liraglutide for The Treatment of Diabetes and Obesity Industry Trends Table 25. Liraglutide for The Treatment of Diabetes and Obesity Industry Drivers Table 26. Liraglutide for The Treatment of Diabetes and Obesity Industry Opportunities and Challenges Table 27. Liraglutide for The Treatment of Diabetes and Obesity Industry Restraints Table 28. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Company (2021-2026) Table 30. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Company (2021-2026) & (K Units) Table 31. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Company (2021-2026) Table 32. Global Liraglutide for The Treatment of Diabetes and Obesity Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Liraglutide for The Treatment of Diabetes and Obesity Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Liraglutide for The Treatment of Diabetes and Obesity Major Company Production Sites and Headquarters Table 35. Global Liraglutide for The Treatment of Diabetes and Obesity Company, Product Type & Application Table 36. Global Liraglutide for The Treatment of Diabetes and Obesity Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Liraglutide for The Treatment of Diabetes and Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2021-2026) & (K Units) Table 41. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Region (2021-2026) Table 42. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2021-2026) & (US$ Million) Table 43. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Region (2021-2026) Table 44. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2027-2032) & (K Units) Table 46. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Region (2027-2032) Table 47. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2027-2032) & (US$ Million) Table 48. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Region (2027-2032) Table 49. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (K Units) Table 52. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application (2021-2026) Table 53. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (US$ Million) Table 54. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application (2021-2026) Table 55. Global Liraglutide for The Treatment of Diabetes and Obesity Price by Application (2021-2026) & (US$/Unit) Table 56. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2027-2032) & (K Units) Table 57. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application (2027-2032) Table 58. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2027-2032) & (US$ Million) Table 59. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application (2027-2032) Table 60. Global Liraglutide for The Treatment of Diabetes and Obesity Price by Application (2027-2032) & (US$/Unit) Table 61. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (K Units) Table 62. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (K Units) Table 64. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (K Units) Table 68. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2021-2026) & (US$ Million) Table 71. Huadong Medicine Company Information Table 72. Huadong Medicine Business Overview Table 73. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 75. Huadong Medicine Recent Development Table 76. Sino Biopharm Company Information Table 77. Sino Biopharm Business Overview Table 78. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 80. Sino Biopharm Recent Development Table 81. Teva Company Information Table 82. Teva Business Overview Table 83. Teva Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 85. Teva Recent Development Table 86. Novo Nordisk Company Information Table 87. Novo Nordisk Business Overview Table 88. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio Table 90. Novo Nordisk Recent Development Table 91. North America Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 92. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026) & (K Units) Table 93. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021-2026) Table 94. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032) & (K Units) Table 95. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Country (2027-2032) Table 96. North America Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 97. North America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026) & (US$ Million) Table 98. North America Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country (2021-2026) Table 99. North America Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032) & (US$ Million) Table 100. North America Liraglutide for The Treatment of Diabetes and Obesity Market Share Forecast by Country (2027-2032) Table 101. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 102. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026) & (K Units) Table 103. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021-2026) Table 104. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032) & (K Units) Table 105. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Country (2027-2032) Table 106. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026) & (US$ Million) Table 108. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country (2021-2026) Table 109. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Share Forecast by Country (2027-2032) Table 111. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026) & (K Units) Table 113. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021-2026) Table 114. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032) & (K Units) Table 115. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Country (2027-2032) Table 116. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026) & (US$ Million) Table 118. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country (2021-2026) Table 119. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Share Forecast by Country (2027-2032) Table 121. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026) & (K Units) Table 123. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021-2026) Table 124. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032) & (K Units) Table 125. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Country (2027-2032) Table 126. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026) & (US$ Million) Table 128. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country (2021-2026) Table 129. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Share Forecast by Country (2027-2032) Table 131. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026) & (K Units) Table 133. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country (2021-2026) Table 134. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Country (2027-2032) Table 136. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026) & (US$ Million) Table 138. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country (2021-2026) Table 139. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Share Forecast by Country (2027-2032) Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Liraglutide for The Treatment of Diabetes and Obesity Distributors List Table 144. Liraglutide for The Treatment of Diabetes and Obesity Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Liraglutide for The Treatment of Diabetes and Obesity Image Figure 2. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 4. Global Liraglutide for The Treatment of Diabetes and Obesity Sales (2021-2032) & (K Units) Figure 5. Generic Drug Image Figure 6. Global Generic Drug Sales YoY Growth (2021-2032) & (K Units) Figure 7. Original Drug Image Figure 8. Global Original Drug Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Liraglutide for The Treatment of Diabetes and Obesity Market Share by Type 2025 VS 2032 Figure 11. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type in 2025 Figure 12. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type in 2025 Figure 13. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type in 2025 Figure 14. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type in 2025 Figure 17. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Liraglutide for The Treatment of Diabetes and Obesity Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 25. Retail Pharmacies Image Figure 26. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Liraglutide for The Treatment of Diabetes and Obesity Market Share by Application 2025 VS 2032 Figure 31. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application in 2025 Figure 32. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application in 2025 Figure 33. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application in 2025 Figure 34. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application in 2025 Figure 37. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share in Value by Application in 2025 Figure 41. North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Liraglutide for The Treatment of Diabetes and Obesity Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Liraglutide for The Treatment of Diabetes and Obesity Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Generic Drug
  • Original Drug
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Huadong Medicine
  • Sino Biopharm
  • Teva
  • Novo Nordisk

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Liraglutide for The Treatment of Diabetes and Obesity Market by Type
  6. 1.3.1 Generic Drug
  7. 1.3.2 Original Drug
  8. 1.4 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size by Type
  9. 1.4.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Liraglutide for The Treatment of Diabetes and Obesity Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Liraglutide for The Treatment of Diabetes and Obesity Industry Trends
  2. 2.2 Liraglutide for The Treatment of Diabetes and Obesity Industry Drivers
  3. 2.3 Liraglutide for The Treatment of Diabetes and Obesity Industry Opportunities and Challenges
  4. 2.4 Liraglutide for The Treatment of Diabetes and Obesity Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Liraglutide for The Treatment of Diabetes and Obesity Revenue (2021-2026)
  2. 3.2 Global Top Players by Liraglutide for The Treatment of Diabetes and Obesity Sales (2021-2026)
  3. 3.3 Global Top Players by Liraglutide for The Treatment of Diabetes and Obesity Price (2021-2026)
  4. 3.4 Global Liraglutide for The Treatment of Diabetes and Obesity Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Liraglutide for The Treatment of Diabetes and Obesity Major Company Production Sites & Headquarters
  6. 3.6 Global Liraglutide for The Treatment of Diabetes and Obesity Company, Product Type & Application
  7. 3.7 Global Liraglutide for The Treatment of Diabetes and Obesity Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Liraglutide for The Treatment of Diabetes and Obesity Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Liraglutide for The Treatment of Diabetes and Obesity Tier 1, Tier 2, and Tier 3
4 Liraglutide for The Treatment of Diabetes and Obesity Regional Status and Outlook
  1. 4.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Liraglutide for The Treatment of Diabetes and Obesity Historic Market Size by Region
  3. 4.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Liraglutide for The Treatment of Diabetes and Obesity Forecasted Market Size by Region
  7. 4.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Liraglutide for The Treatment of Diabetes and Obesity by Application
  1. 5.1 Liraglutide for The Treatment of Diabetes and Obesity Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size by Application
  6. 5.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Liraglutide for The Treatment of Diabetes and Obesity Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Huadong Medicine
  2. 6.1.1 Huadong Medicine Company Information
  3. 6.1.2 Huadong Medicine Business Overview
  4. 6.1.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  6. 6.1.5 Huadong Medicine Recent Developments
  7. 6.2 Sino Biopharm
  8. 6.2.1 Sino Biopharm Company Information
  9. 6.2.2 Sino Biopharm Business Overview
  10. 6.2.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  12. 6.2.5 Sino Biopharm Recent Developments
  13. 6.3 Teva
  14. 6.3.1 Teva Company Information
  15. 6.3.2 Teva Business Overview
  16. 6.3.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  18. 6.3.5 Teva Recent Developments
  19. 6.4 Novo Nordisk
  20. 6.4.1 Novo Nordisk Company Information
  21. 6.4.2 Novo Nordisk Business Overview
  22. 6.4.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolio
  24. 6.4.5 Novo Nordisk Recent Developments
7 North America by Country
  1. 7.1 North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
  2. 7.1.1 North America Liraglutide for The Treatment of Diabetes and Obesity Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026)
  4. 7.1.3 North America Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032)
  5. 7.2 North America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country
  6. 7.2.1 North America Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026)
  8. 7.2.3 North America Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
  2. 8.1.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026)
  4. 8.1.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country
  6. 8.2.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026)
  8. 8.2.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
  2. 9.1.1 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country
  6. 9.2.1 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
  2. 10.1.1 South America Liraglutide for The Treatment of Diabetes and Obesity Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026)
  4. 10.1.3 South America Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032)
  5. 10.2 South America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country
  6. 10.2.1 South America Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026)
  8. 10.2.3 South America Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
  2. 11.1.1 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country
  6. 11.2.1 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Liraglutide for The Treatment of Diabetes and Obesity Value Chain Analysis
  2. 12.1.1 Liraglutide for The Treatment of Diabetes and Obesity Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Liraglutide for The Treatment of Diabetes and Obesity Production Mode & Process
  7. 12.2 Liraglutide for The Treatment of Diabetes and Obesity Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
  10. 12.2.3 Liraglutide for The Treatment of Diabetes and Obesity Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst